Ann: Afamelanotide well tolerated by first stroke patients, page-6

Once again the person at the ASX who determines if an announcement is 'market sensitive' or not is a bit overloaded today and missed this one. Previously from the Clinuvel manager: “Our unambiguous aim is to develop a treatment for 70% to 80% of the stroke patients who currently have no alternative treatment” That would be 70 - 80% of 15 MILLION UNTREATED STROKES PER YEAR. And today from the same manager: “On the basis of the first three patients, there is a prospect that CLINUVEL will be able to treat many more stroke patients than initially anticipated, since one third of stroke patients globally have underlying heart problems". It is not some new drug without any approvals either, the drug is already approved by the FDA, TGA and EMA so it is only seeking a new indication in an untapped market and the drug is already proven safe. Conducting a trial in this COVID ravaged world is no small thing either. The news is BIG. The company is undervalued imo and I will be buying more CUV.